Fed. Circ. Upholds Rejection Of 2 Endo Opana Patents

Law360, Washington (May 13, 2011, 8:23 PM EDT) -- The Federal Circuit on Friday revived a nixed Endo Pharmaceuticals Inc. drug patent application related to a formulation of the painkiller Opana, but affirmed the U.S. Patent and Trademark Office's rejection of two other related patents.

Endo is the assignee of three patent applications related to controlled-release tablets containing the opioid narcotic oxymorphone, U.S. Patent Numbers 11/680,432; 12/167,859; and 11/766,740. The Board of Patent Appeals and Interferences, in separate appeals, affirmed the rejection of the claims of each application as obvious, and Endo appealed each decision...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.